Variance based global sensitivity analysis of physiologically based pharmacokinetic absorption models for BCS I–IV drugsCitation formats

Standard

Variance based global sensitivity analysis of physiologically based pharmacokinetic absorption models for BCS I–IV drugs. / Melillo, Nicola; Aarons, Leon; Magni, Paolo; Darwich, Adam S.

In: Journal of pharmacokinetics and pharmacodynamics, Vol. 46, No. 1, 15.02.2019, p. 27-42.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Melillo, Nicola ; Aarons, Leon ; Magni, Paolo ; Darwich, Adam S. / Variance based global sensitivity analysis of physiologically based pharmacokinetic absorption models for BCS I–IV drugs. In: Journal of pharmacokinetics and pharmacodynamics. 2019 ; Vol. 46, No. 1. pp. 27-42.

Bibtex

@article{449b4edf4706426897b0972d091c6cff,
title = "Variance based global sensitivity analysis of physiologically based pharmacokinetic absorption models for BCS I–IV drugs",
abstract = "Regulatory agencies have a strong interest in sensitivity analysis for the evaluation of physiologically-based pharmacokinetic (PBPK) models used in pharmaceutical research and drug development and regulatory submissions. One of the applications of PBPK is the prediction of fraction absorbed and bioavailability for drugs following oral administration. In this context, we performed a variance based global sensitivity analysis (GSA) on in-house PBPK models for drug absorption, with the aim of identifying key parameters that influence the predictions of the fraction absorbed and the bioavailability for neutral, acidic and basic compounds. This analysis was done for four different classes of drugs, defined according to the Biopharmaceutics Classification System, differentiating compounds by permeability and solubility. For class I compounds (highly permeable, highly soluble), the parameters that mainly influence the fraction absorbed are related to the formulation properties, for class II compounds (highly permeable, lowly soluble) to the dissolution process, for class III (lowly permeable, highly soluble) to both absorption process and formulation properties and for class IV (lowly permeable, lowly soluble) to both absorption and dissolution processes. Considering the bioavailability, the results are similar to those for the fraction absorbed, with the addition that parameters related to gut wall and liver clearance influence as well the predictions. This work aimed to give a demonstration of the GSA methodology and highlight its importance in improving our understanding of PBPK absorption models and in guiding the choice of parameters that can safely be assumed, estimated or require data generation to allow informed model prediction.",
keywords = "BCS, Drug absorption, Global sensitivity analysis, Oral bioavailability, PBPK, Variance based GSA",
author = "Nicola Melillo and Leon Aarons and Paolo Magni and Darwich, {Adam S.}",
year = "2019",
month = feb,
day = "15",
doi = "10.1007/s10928-018-9615-8",
language = "English",
volume = "46",
pages = "27--42",
journal = "Journal of pharmacokinetics and pharmacodynamics",
issn = "1573-8744",
publisher = "Springer Nature",
number = "1",

}

RIS

TY - JOUR

T1 - Variance based global sensitivity analysis of physiologically based pharmacokinetic absorption models for BCS I–IV drugs

AU - Melillo, Nicola

AU - Aarons, Leon

AU - Magni, Paolo

AU - Darwich, Adam S.

PY - 2019/2/15

Y1 - 2019/2/15

N2 - Regulatory agencies have a strong interest in sensitivity analysis for the evaluation of physiologically-based pharmacokinetic (PBPK) models used in pharmaceutical research and drug development and regulatory submissions. One of the applications of PBPK is the prediction of fraction absorbed and bioavailability for drugs following oral administration. In this context, we performed a variance based global sensitivity analysis (GSA) on in-house PBPK models for drug absorption, with the aim of identifying key parameters that influence the predictions of the fraction absorbed and the bioavailability for neutral, acidic and basic compounds. This analysis was done for four different classes of drugs, defined according to the Biopharmaceutics Classification System, differentiating compounds by permeability and solubility. For class I compounds (highly permeable, highly soluble), the parameters that mainly influence the fraction absorbed are related to the formulation properties, for class II compounds (highly permeable, lowly soluble) to the dissolution process, for class III (lowly permeable, highly soluble) to both absorption process and formulation properties and for class IV (lowly permeable, lowly soluble) to both absorption and dissolution processes. Considering the bioavailability, the results are similar to those for the fraction absorbed, with the addition that parameters related to gut wall and liver clearance influence as well the predictions. This work aimed to give a demonstration of the GSA methodology and highlight its importance in improving our understanding of PBPK absorption models and in guiding the choice of parameters that can safely be assumed, estimated or require data generation to allow informed model prediction.

AB - Regulatory agencies have a strong interest in sensitivity analysis for the evaluation of physiologically-based pharmacokinetic (PBPK) models used in pharmaceutical research and drug development and regulatory submissions. One of the applications of PBPK is the prediction of fraction absorbed and bioavailability for drugs following oral administration. In this context, we performed a variance based global sensitivity analysis (GSA) on in-house PBPK models for drug absorption, with the aim of identifying key parameters that influence the predictions of the fraction absorbed and the bioavailability for neutral, acidic and basic compounds. This analysis was done for four different classes of drugs, defined according to the Biopharmaceutics Classification System, differentiating compounds by permeability and solubility. For class I compounds (highly permeable, highly soluble), the parameters that mainly influence the fraction absorbed are related to the formulation properties, for class II compounds (highly permeable, lowly soluble) to the dissolution process, for class III (lowly permeable, highly soluble) to both absorption process and formulation properties and for class IV (lowly permeable, lowly soluble) to both absorption and dissolution processes. Considering the bioavailability, the results are similar to those for the fraction absorbed, with the addition that parameters related to gut wall and liver clearance influence as well the predictions. This work aimed to give a demonstration of the GSA methodology and highlight its importance in improving our understanding of PBPK absorption models and in guiding the choice of parameters that can safely be assumed, estimated or require data generation to allow informed model prediction.

KW - BCS

KW - Drug absorption

KW - Global sensitivity analysis

KW - Oral bioavailability

KW - PBPK

KW - Variance based GSA

UR - http://www.scopus.com/inward/record.url?scp=85058490900&partnerID=8YFLogxK

U2 - 10.1007/s10928-018-9615-8

DO - 10.1007/s10928-018-9615-8

M3 - Article

VL - 46

SP - 27

EP - 42

JO - Journal of pharmacokinetics and pharmacodynamics

JF - Journal of pharmacokinetics and pharmacodynamics

SN - 1573-8744

IS - 1

ER -